CLDX vs MYGN
Celldex Therapeutics, Inc. and Myriad Genetics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CLDX | MYGN |
|---|---|---|
| Revenue | $1.5M | $824.5M |
| Net income | $-258.8M | $-365.9M |
| Gross margin | 87.1% | 69.9% |
| Net margin | −16748.0% | −44.4% |
| Return on equity | −40.6% | −68.5% |
| Diluted EPS | −$3.90 | −$3.95 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-213.7M | $-151.6M |
| Equity | $527.2M | $368.0M |
| Net debt / equity | −0.14× | −0.08× |
| Current ratio | 10.49× | 2.49× |
| Revenue CAGR 5y | −26.9% | 8.2% |
| Profit CAGR 5y | — | — |
MYGN bills 533.7× the revenue of CLDX, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | CLDX | MYGN |
|---|---|---|
| FY2025 | $1.5M | $824.5M |
| FY2024 | $7.0M | $837.6M |
| FY2023 | $6.9M | $753.2M |
| FY2022 | $2.4M | $678.4M |
| FY2021 | $4.7M | $690.6M |
| FY2020 | $7.4M | $557.1M |
| FY2019 | $3.6M | $638.6M |
| FY2018 | $9.5M | $851.1M |
| FY2017 | $12.7M | $743.7M |
| FY2016 | $6.8M | $728.7M |
Net income by year
Bottom line
| Fiscal year | CLDX | MYGN |
|---|---|---|
| FY2025 | $-258.8M | $-365.9M |
| FY2024 | $-157.9M | $-127.3M |
| FY2023 | $-141.4M | $-263.3M |
| FY2022 | $-112.3M | $-112.0M |
| FY2021 | $-70.5M | $-27.2M |
| FY2020 | $-59.8M | $-223.6M |
| FY2019 | $-50.9M | $-199.5M |
| FY2018 | $-151.2M | $4.6M |
| FY2017 | $-93.0M | $133.3M |
| FY2016 | $-128.5M | $17.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry